港股異動 | 同仁堂國藥(3613.HK)漲超8% 2020年中國內地收入大增41.9%
格隆匯3月12日丨同仁堂國藥(3613.HK)大幅拉昇至8.27%,報11港元,總市值92億港元。
同仁堂國藥2020年度純利減少2.5%至5.42億港元,末期息0.24港元,較2019年0.23港元有所增加。報吿期內,來自香港市場和海外市場的收入分別下降30.9%和0.3%,而來自中國內地市場的收入則大增41.9%。
於2020年12月31日,累計獲授權的專利共有53件(包括中國內地、香港專利)及開展PCT國際申請2件,此外還開展了14項着作權的申請,均已獲得作品登記證書,為同仁堂的優勢品種樹起了良好的保護屏障。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.